Anti-uPA (human, urokinase plasminogen activator)
Mouse monoclonal antibody
Cat.No. MON U-16
Preparation: Protein-A purified
Content: Available in 200 µL and 1 mL
Concentration: 1 mg/mL
Solvent: 0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15 mM sodium azide
Storage: In the dark at 4-8ºC
Urokinase plasminogen activator (uPA) is a serine protease. It converts the abundant proenzyme plasminogen to active plasmin and plays a key role in cancer invasion and a variety of tissue remodelling processes such as wound healing, mammary gland involution and placental development (1-3). Elevated levels of uPA are associated with poor prognosis in many types of cancer (2-5).
Native human uPA
MON U-16 is specific for human uPA. No reaction with human tissue plasminogen activator (tPA) when tested by ELISA, immunoblotting and enzyme inhibition and no reaction with any other human plasma proteins when tested by immunoblotting.
MON U-16 binds to the B-chain of uPA (6)
MON U-16 binds single and two-chain uPA and uPA/PAI-1 complexes. A reaction is seen with LMW-uPA but not with amino terminal fregment (ATF). MON U-16 is recommended for flowcytometry and immunoflourescence studies (6) and can be used on frozen sections in immunohistochemistry applications.
| Method | Usability | Dilution guideline | References |
| ELISA | Yes | 5 | |
| Immunoblotting | Yes | ||
| Immunohistochemistry | Yes |
1. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44:139-266.
2. Andreasen PA, Kjøller L, Christensen L, Duffey MJ (1997) The urokinase plasminogen activator system in cancer metastasis. Int J Cancer 2:1-22.
3. Danø K, Behrendt N, Høyer-Hansen G, Johnsen M, Lund LR, Ploug M, Rømer J (2005) Plasminogen activation and cancer. Thromb Haem 93:676-681.
4. Harbeck N, Kates RE, Look MP (2002) Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk acording to urokinase -type plasminogen activator and plasminogen activator inhibitor type 1 (n=3424). Cancer Res 62:4617-22.
5. Pedersen AN, Høyer-Hansen G, Brünner N, Clark GM, Larsen B, Poulsen HS, Danø K, Stephens RW (1997) The complex between urokinase plasminogen activator and its type-1 inhibitor in breast cancer extracts quantitated by ELISA. J Imm Meth 203:55-65.
6. Kaltoft K, Nielsen LS, Zeuthen J, Danø K (1982) Monoclonal antibody that specifically inhibits a human Mr 52,000 plasminogen-activating enzyme. Proc Natl Acad Sci USA 79:3720-3723.
7. Plesner T, Ploug M, Ellis V, Rønne E, Høyer-Hansen G, Wittrup M, Pedersen TL, Tscherning T, Danø K, Hansen NE ( 1994) The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the pl asma membrane on stimulation of human neutrophils. Blood 83:808-815.
